Ken Kengatharan

San Francisco bay area based evergreen healthcare incubator fund focusing on opportunities in orphan drugs and rare diseases. Previously he was President and CEO of Armetheon (renamed Espero Biopharma following a merger) and prior to that President and CSO of Athos. He is the former Vice President of, Pre-Clinical R&D of Athenagen (re-named CoMentis following a merger).

During the last 20 years, Dr. Kengatharan has been critical to the development of multiple drug candidates from concept to clinical development. Since setting up his first company in the late 1990s, with a great team and highly supportive investors in each case, he has been critical to setting-up multiple companies and raising >$160MM in private equity, and closing partnership transactions in excess of $1bn in deal value. He has served on the boards of EPi3 (UK), Athenagen, Athos, Armetheon, he has been an advisor/advisory board member at Spire-BioVentures, Cardinal Free Clinics (Stanford University School of Medicine), a mentor at the University of California, San Francisco (UCSF)’s entrepreneurship program and a panel judge for the Stanford Business School’s Ignite Program. He trained as a cardiovascular pharmacologist in London and at Stanford after obtaining his Ph.D. in pharmacology from the University of London under the supervision of eminent British pharmacologist and Nobel laureate, Prof. Sir John Vane FRS and Professor Christoph Thiemermann. Dr. Kengatharan obtained his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship. His current interests, based on previous experience, include capital-efficient R&D, application of distributed ledger technology, AI, and novel paths to raising private equity, in healthcare.